// App-Quantinova.ai

: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

Researchers

Presenter

  • GEORGE E. DAILEY III

Principal Investigators

  • JULIO ROSENSTOCK

  • CRISTOBAL MORALES SR

  • ULRICH WENDISCH

  • MICHAEL E. TRAUTMANN

  • MARCUS HOMPESCH

  • IN YOUNG CHOI

  • JAHOON KANG

  • CHRISTOPHER H. SORLI

  • IKE OGBAA

  • JOHN A. STEWART

Medical Centers

  • N/A

Locations

  • United States

  • Spain

  • Germany

  • Canada

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Endocrine/metabolic Diseases (ME)

Disease

  • Type 2 diabetes mellitus

Biomarkers

  • Hemoglobin A1c

  • Body mass index

Drug/Treatment

  • Efpeglenatide

  • Metformin Hydrochloride

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved